001     292074
005     20250731110849.0
024 7 _ |a 10.1002/ijc.35114
|2 doi
024 7 _ |a pmid:39057841
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:165755066
|2 altmetric
037 _ _ |a DKFZ-2024-01582
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Li, Jinze
|0 0000-0003-0082-7393
|b 0
245 _ _ |a Pre-diagnostic plasma advanced glycation end-products and soluble receptor for advanced glycation end-products and mortality in colorectal cancer patients.
260 _ _ |a Bognor Regis
|c 2024
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1730278867_22133
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Dec 1;155(11):1982-1995
520 _ _ |a Advanced glycation end-products (AGEs), formed endogenously or obtained exogenously from diet, may contribute to chronic inflammation, intracellular signaling alterations, and pathogenesis of several chronic diseases including colorectal cancer (CRC). However, the role of AGEs in CRC survival is less known. The associations of pre-diagnostic circulating AGEs and their soluble receptor (sRAGE) with CRC-specific and overall mortality were estimated using multivariable-adjusted Cox proportional hazards regression among 1369 CRC cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Concentrations of major plasma AGEs, Nε-[carboxy-methyl]lysine (CML), Nε-[carboxy-ethyl]lysine (CEL) and Nδ-[5-hydro-5-methyl-4-imidazolon-2-yl]-ornithine (MG-H1), were measured using ultra-performance liquid chromatography mass-spectrometry. sRAGE was assessed by enzyme-linked immunosorbent assay. Over a mean follow-up period of 96 months, 693 deaths occurred of which 541 were due to CRC. Individual and combined AGEs were not statistically significantly associated with CRC-specific or overall mortality. However, there was a possible interaction by sex for CEL (Pinteraction = .05). Participants with higher sRAGE had a higher risk of dying from CRC (HRQ5vs.Q1 = 1.67, 95% CI: 1.21-2.30, Ptrend = .02) or any cause (HRQ5vs.Q1 = 1.38, 95% CI: 1.05-1.83, Ptrend = .09). These associations tended to be stronger among cases with diabetes (Pinteraction = .03) and pre-diabetes (Pinteraction <.01) before CRC diagnosis. Pre-diagnostic AGEs were not associated with CRC-specific and overall mortality in individuals with CRC. However, a positive association was observed for sRAGE. Our findings may stimulate further research on the role of AGEs and sRAGE in survival among cancer patients with special emphasis on potential effect modifications by sex and diabetes.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a advanced glycation end‐products (AGEs)
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a mortality
|2 Other
650 _ 7 |a soluble receptor of AGEs (sRAGE)
|2 Other
700 1 _ |a Roshelli Baker, Jacqueline
|b 1
700 1 _ |a Aglago, Elom K
|0 0000-0002-0442-3284
|b 2
700 1 _ |a Zhao, Zhiwei
|b 3
700 1 _ |a Jiao, Li
|0 0000-0002-0237-0262
|b 4
700 1 _ |a Freisling, Heinz
|0 0000-0001-8648-4998
|b 5
700 1 _ |a Hughes, David J
|b 6
700 1 _ |a Eriksen, Anne Kirstine
|b 7
700 1 _ |a Tjønneland, Anne
|b 8
700 1 _ |a Severi, Gianluca
|0 0000-0001-7157-419X
|b 9
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 10
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 11
|u dkfz
700 1 _ |a Schulze, Matthias B
|b 12
700 1 _ |a Masala, Giovanna
|b 13
700 1 _ |a Pala, Valeria
|0 0000-0001-5438-970X
|b 14
700 1 _ |a Pasanisi, Fabrizio
|b 15
700 1 _ |a Tumino, Rosario
|b 16
700 1 _ |a Padroni, Lisa
|b 17
700 1 _ |a Vermeulen, Roel C H
|b 18
700 1 _ |a Gram, Inger T
|0 0000-0002-0031-4152
|b 19
700 1 _ |a Braaten, Tonje
|b 20
700 1 _ |a Jakszyn, Paula Gabriela
|b 21
700 1 _ |a Sánchez, Maria-José
|b 22
700 1 _ |a Gómez-Gómez, Jesús-Humberto
|b 23
700 1 _ |a Moreno-Iribas, Conchi
|b 24
700 1 _ |a Amiano, Pilar
|b 25
700 1 _ |a Papier, Keren
|b 26
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 27
700 1 _ |a Huybrechts, Inge
|b 28
700 1 _ |a Heath, Alicia K
|0 0000-0001-6517-1300
|b 29
700 1 _ |a Schalkwijk, Casper
|b 30
700 1 _ |a Jenab, Mazda
|0 0000-0002-0573-1852
|b 31
700 1 _ |a Fedirko, Veronika
|0 0000-0002-7805-9913
|b 32
773 _ _ |a 10.1002/ijc.35114
|g p. ijc.35114
|0 PERI:(DE-600)1474822-8
|n 11
|p 1982-1995
|t International journal of cancer
|v 155
|y 2024
|x 0020-7136
856 4 _ |u https://inrepo02.dkfz.de/record/292074/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Li%20-%20Pre%E2%80%90diagnostic%20plasma%20advanced%20glycation%20end%E2%80%90products%20and%20soluble%20receptor%20for.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292074/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Li%20-%20Pre%E2%80%90diagnostic%20plasma%20advanced%20glycation%20end%E2%80%90products%20and%20soluble%20receptor%20for.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:292074
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21